---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-002844"
form_type: "8-K"
ticker: "VVOS"
cik: "0001716166"
company_name: "Vivos Therapeutics, Inc."
filed_at: "2026-01-20T23:59:59+00:00"
generated_at: "2026-05-16T09:34:09.679446+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vivos Therapeutics raises $4.6M via warrant exercise and issues new warrants for 3.96M shares

## Summary
- Gross proceeds of ~$4.6M from immediate cash exercise of existing warrants at reduced price of $2.34/share.
- Issued Series A (5-yr) and Series B (24-mo) warrants to purchase up to 3,964,712 shares at $2.09/share.
- Must file resale registration for new warrant shares by Feb 14, 2026; effective by Mar 16 or Apr 15 if SEC review.
- Placement agent H.C. Wainwright paid 7% cash fee and received warrants for 138,765 shares at $2.925/share.
- Until Feb 19, 2026, company restricted from issuing additional shares or filing registration statements.

## SEC filing metadata
- accession: 0001493152-26-002844
- form_type: 8-K
- ticker: VVOS
- cik: 0001716166
- company_name: Vivos Therapeutics, Inc.
- filed_at: 2026-01-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716166/000149315226002844/0001493152-26-002844-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716166/000149315226002844/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-002844
- JSON: https://secwatch.observer/filing/0001493152-26-002844.json
- Plain text: https://secwatch.observer/filing/0001493152-26-002844.txt

## Key facts
- Material Agreements
  Vivos Therapeutics, Inc. entered into Warrant Inducement Letter Agreement with an institutional investor valued at The Company agreed to issue warrants to purchase up to 3,964,712 shares of Common Stock at an exerci (effective 2026-01-15).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: an institutional investor
  - Value: The Company agreed to issue warrants to purchase up to 3,964,712 shares of Common Stock at an exerci
  - Effective: 2026-01-15
  source text: On January 15, 2026, the Company entered into a warrant inducement letter agreement with the Holder (the “ Inducement Agreement ”) pursuant to which the Holder agreed to exercise for cash the entirety of the Warrants at a reduced exercise price of $2.34 per share (with such exercise price being established for purposes of compliance with the listing rules of the Nasdaq Stock Market), resulting in gross proceeds to the Company of approximately $4.6 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1716166/000149315226002844/0001493152-26-002844-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.